Autres langues FSD Pharma Inc.

Actions

HUGE

CA35954B4047

Marché Fermé - Canadian Securities Exchange Autres places de cotation 21:59:02 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,52 ^CAD	+1,96 %		-21,21 %	-56,67 %

30/04	FSD Pharma Inc. signe un accord avec Applied Science and Performance Institute pour mener un essai clinique aux États-Unis afin d'évaluer l'innocuité et l'efficacité d'Unbuzzd ? dans un état d'intoxication alcoolique induit	CI
25/04	FSD Pharma annonce que Celly Nutrition s'associe à Six+One pour le lancement de son complément alimentaire aux Etats-Unis	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

FSD Pharma Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd in an Induced State of Alcohol Intoxication	01/05
FSD Pharma : Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy ofunbuzzd™ in an Induced State of Alcohol Intoxication - Form 6-K	30/04
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	30/04
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd	26/04
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	25/04
FSD Pharma Provides another Update on Celly Nu's Anticipated Launch of unbuzzd	23/04
FSD Pharma : Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products - Form 6-K	17/04
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption	16/04
FSD Pharma Receives Nasdaq Non-Compliance Notice	08/04
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	08/04
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
FSD Pharma Signs the Agreement With iNGENu CRO to Conduct a Clinical Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adults	28/03
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	27/03
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	27/03
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	11/03
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	11/03
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 at Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	06/03
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	05/03
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	05/03
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues FSD Pharma Inc.

Actions

HUGE

CA35954B4047

Autres langues

Filtres